{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:23:37Z","timestamp":1792484617632,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017325","name":"National Science Foundation Engineering Research Centers","doi-asserted-by":"publisher","award":["1648035"],"award-info":[{"award-number":["1648035"]}],"id":[{"id":"10.13039\/100017325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015982","name":"Midwest Athletes Against Childhood Cancer","doi-asserted-by":"publisher","award":["R35 GM119644-01"],"award-info":[{"award-number":["R35 GM119644-01"]}],"id":[{"id":"10.13039\/100015982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["\/ NCI R01 CA278051"],"award-info":[{"award-number":["\/ NCI R01 CA278051"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1S10RR025483-01"],"award-info":[{"award-number":["1S10RR025483-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020317","name":"Grainger Institute for Engineering, University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008959","name":"College of Engineering, University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ymthe.2025.01.024","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T11:44:16Z","timestamp":1736855056000},"page":"1014-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells"],"prefix":"10.1016","volume":"33","author":[{"given":"Keerthana","family":"Shankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Zingler-Hoslet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Tabima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Zima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstan","family":"Gimse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Katta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sage Z.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany E.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdar Q.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Capitini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-0858","authenticated-orcid":false,"given":"Krishanu","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.01.024_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib4","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fonc.2019.00051","article-title":"Overcoming resistance to natural killer cell based immunotherapies for solid tumors","volume":"9","author":"Nayyar","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib9","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.01.024_bib10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.01.024_bib11","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.01.024_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2081415","article-title":"CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma","volume":"11","author":"Bexte","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2025.01.024_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1231916","article-title":"KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors","volume":"14","author":"Mac Donald","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib14","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.01.024_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cell.2019.05.035","article-title":"The cytoplasmic DNA sensor cGAS promotes mitotic cell death","volume":"178","author":"Zierhut","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.01.024_bib16","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.15252\/embr.201744017","article-title":"cGAS is activated by DNA in a length-dependent manner","volume":"18","author":"Luecke","year":"2017","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ymthe.2025.01.024_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib18","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.01.024_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cgt.2009.61","article-title":"Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.01.024_bib20","article-title":"Non-Viral Engineering of CAR-NK and CAR-T cells using the Tc Buster Transposon SystemTM","author":"Pomeroy","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2025.01.024_bib21","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2025.01.024_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41587-022-01418-8","article-title":"High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails","volume":"41","author":"Shy","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","article-title":"Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency","volume":"38","author":"Nguyen","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib24","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2023020973","article-title":"Integration of \u03b6-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.01.024_bib25","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/15258160152509145","article-title":"Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92","volume":"10","author":"Tonn","year":"2001","journal-title":"J.\u00a0Hematother. Stem Cell Res."},{"key":"10.1016\/j.ymthe.2025.01.024_bib27","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2025.01.024_bib28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2025.01.024_bib29","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib30","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.01.024_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-020-01741-4","article-title":"Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies","volume":"11","author":"Shankar","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2025.01.024_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T\u00a0cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.01.024_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for improving HDR efficiency","volume":"9","author":"Liu","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2025.01.024_bib34","article-title":"Production and characterization of virus-free, CRISPR-CAR T\u00a0cells capable of inducing solid tumor regression","volume":"10","author":"Mueller","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.01.024_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.01.024_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41587-023-01779-8","article-title":"A highly efficient transgene knock-in technology in clinically relevant cell types","volume":"42","author":"Allen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.01.024_bib39","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Naeimi Kararoudi","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.ymthe.2025.01.024_bib40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/d41586-023-03590-6","article-title":"UK first to approve CRISPR treatment for diseases: what you need to know","volume":"623","author":"Wong","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.01.024_bib41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ymthe.2024.01.015","article-title":"A new frontier: FDA approvals for gene therapy in sickle cell disease","volume":"32","author":"Leonard","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.01.024_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.01.024_bib46","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1038\/s41467-022-30515-0","article-title":"CRISPR\/Cas9 gRNA activity depends on free energy changes and on the target PAM context","volume":"13","author":"Corsi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.01.024_bib47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.immuni.2013.05.004","article-title":"Immune sensing of DNA","volume":"38","author":"Paludan","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.01.024_bib48","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.01.024_bib49","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in\u00a0vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.01.024_bib50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fimmu.2017.00676","article-title":"A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma","volume":"8","author":"Wagner","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib51","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2021-152356","article-title":"A novel method for highly efficient ex\u00a0vivo expansion and genetic engineering of human natural killer cells for cancer therapy","volume":"138","author":"Kubo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.01.024_bib52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib53","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.01.024_bib54","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","article-title":"Minimap2: pairwise alignment for nucleotide sequences","volume":"34","author":"Li","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.01.024_bib55","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1093\/bioinformatics\/btab366","article-title":"DetectIS: a pipeline to rapidly detect exogenous DNA integration sites using DNA or RNA paired-end sequencing data","volume":"37","author":"Grassi","year":"2021","journal-title":"Bioinformatics"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625000280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625000280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:47:01Z","timestamp":1778816821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625000280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1525001625000280"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.024","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}